Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (21)

I-73Ioannis Loisios-Konstantinidis

Combining physiologically based pharmacokinetic modeling and simulations and allometry to inform the starting dose of asciminib in pediatric patients

Wednesday 10:00-11:30

I-79Belén Pérez Solans

Pharmacokinetic analysis across studies to drive knowledge-integration: optimal dose finding of rifampicin for the treatment of drug-susceptible tuberculosis in children

Wednesday 10:00-11:30

I-80Soumya Perinparajah

Modelling the pharmacodynamics of rituximab biosimilar in children with rheumatological conditions

Wednesday 10:00-11:30

I-81Anne Ravix

Dosing optimization of amoxicillin in children treated for Lyme disease

Wednesday 10:00-11:30

I-82Leyanis Rodriguez Vera

Showcasing the potential of PBPK modeling to inform drug-drug interactions specific recommendations for pediatric labeling: omeprazol case example

Wednesday 10:00-11:30

I-84Stephan Schaller

Using PBPK Modeling to support an adaptive “First-in-Pediatric” trial design of Sonlicromanol for the treatment of Primary Mitochondrial Disease

Wednesday 10:00-11:30

I-85Maja Skataric

Dabrafenib and Trametinib dose optimization in 6-17 year old tumor agnostic patients based on established efficacy surrogate targets in adults

Wednesday 10:00-11:30

I-86Melina Steichert

Enalapril orodispersible minitablets for pediatric heart failure – a population pharmacokinetic analysis from multicenter Phase II/III LENA clinical trials

Wednesday 10:00-11:30

I-87

Population pharmacokinetic and exposure-response analysis for ambrisentan for the treatment of pulmonary arterial hypertension in paediatric subjects aged 8 to less than 18 years.

Wednesday 10:00-11:30

I-90Lufina Tsirizani

Population pharmacokinetics of ritonavir-boosted darunavir in children aged 3 to 15 years in the CHAPAS 4 trial living with HIV in Africa.

Wednesday 10:00-11:30

II-98Jen-Hao (Eric) Wu

Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – results of study ITCC-059

Wednesday 15:35-17:00

III-05Fan Cheng

Favipiravir pharmacokinetics in immunocompromised infants and children with chronic RNA viral infections

Thursday 10:15-11:45

III-06S. Y. Amy Cheung

Predicting RSV prophylaxis in the infant target population – assessing monoclonal antibody versus maternal vaccination efficacy using MBMA

Thursday 10:15-11:45

III-07Marc Codaccioni

Predictive performance of two hepatic CYP3A4 ontogeny within a paediatric PBPK model.

Thursday 10:15-11:45

III-08Alessandro Di Deo

A model-based algorithm for mycophenolate dose adjustment in paediatric transplantation patients

Thursday 10:15-11:45

III-11Klervi GOLHEN

Characterizing effect of methotrexate on adalimumab PK in pediatric patients with inflammatory rheumatic disease

Thursday 10:15-11:45

III-12Silvia Grandoni

Efficacy extrapolation and dose rationale for duloxetine in paediatric chronic pain

Thursday 10:15-11:45

III-21Feras Khalil

A joint parent-metabolite model to characterize the pharmacokinetic profile of tapentadol and its metabolites in the pediatric population and inform a model-based evaluation of a post-approval commitment pediatric trial

Thursday 10:15-11:45

III-34Xia Li

Model Informed Dose Evaluation for Aticaprant in Adolescent Patients Following the Adult Dose Regimen

Thursday 10:15-11:45

III-91Anne van Rongen

Quantification of renal drug clearance in neonates born Small for Gestational Age (SGA) compared to neonates born Appropriate for Gestational Age (AGA)

Thursday 10:15-11:45

III-93Yunjiao Wu

When will the glomerular filtration rate in preterm neonates catch up to their term peers?

Thursday 10:15-11:45